DEWIDAR, O., T. LOTFI, M. LANGENDAM, E. PARMELLI, Z. SAZ PARKINSON, K. SOLO, D. K. CHU, J. L. MATHEW, E. A. AKL, R. BRIGNARDELLO-PETERSEN, R. A. MUSTAFA, L. MOJA, A. IORIO, Y. CHI, C. CANELO-AYBAR, T. KREDO, J. KARPUSHEFF, A. F. TURGEON, P. ALONSO-COELLO, W. WIERCIOCH, A. GERRITSEN, Miloslav KLUGAR, M. X. ROJAS, P. TUGWELL, V. A. WELCH, K. POTTIE, Z. MUNN, R. NIEUWLAAT, N. FORD, A. STEVENS, J. KHABSA, Z. NASIR, G. I. LEONTIADIS, J. J. MEERPOHL, T. PIGGOTT, A. QASEEM, M. MATTHEWS a H. J. SCHÜNEMANN. Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal. BMJ EVIDENCE-BASED MEDICINE. London: BMJ PUBLISHING GROUP, 2022, roč. 27, č. 6, s. 361-369. ISSN 2515-446X. Dostupné z: https://dx.doi.org/10.1136/bmjebm-2021-111866.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal
Autoři DEWIDAR, O., T. LOTFI, M. LANGENDAM, E. PARMELLI, Z. SAZ PARKINSON, K. SOLO, D. K. CHU, J. L. MATHEW, E. A. AKL, R. BRIGNARDELLO-PETERSEN, R. A. MUSTAFA, L. MOJA, A. IORIO, Y. CHI, C. CANELO-AYBAR, T. KREDO, J. KARPUSHEFF, A. F. TURGEON, P. ALONSO-COELLO, W. WIERCIOCH, A. GERRITSEN, Miloslav KLUGAR (203 Česká republika, domácí), M. X. ROJAS, P. TUGWELL, V. A. WELCH, K. POTTIE, Z. MUNN, R. NIEUWLAAT, N. FORD, A. STEVENS, J. KHABSA, Z. NASIR, G. I. LEONTIADIS, J. J. MEERPOHL, T. PIGGOTT, A. QASEEM, M. MATTHEWS a H. J. SCHÜNEMANN (garant).
Vydání BMJ EVIDENCE-BASED MEDICINE, London, BMJ PUBLISHING GROUP, 2022, 2515-446X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30218 General and internal medicine
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.800
Kód RIV RIV/00216224:14110/22:00126087
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1136/bmjebm-2021-111866
UT WoS 000783808300001
Klíčová slova anglicky COVID-19; Evidence-Based Practice; Health Services Research
Štítky 14119612, 14119613, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 16. 1. 2023 14:28.
Anotace
Objectives To evaluate the development and quality of actionable statements that qualify as good practice statements (GPS) reported in COVID-19 guidelines. Design and setting Systematic review . We searched MEDLINE, MedSci, China National Knowledge Infrastructure (CNKI), databases of Grading of Recommendations Assessment, Development and Evaluation (GRADE) Guidelines, NICE, WHO and Guidelines International Network (GIN) from March 2020 to September 2021. We included original or adapted recommendations addressing any COVID-19 topic. Main outcome measures We used GRADE Working Group criteria for assessing the appropriateness of issuing a GPS: (1) clear and actionable; (2) rationale necessitating the message for healthcare practice; (3) practicality of systematically searching for evidence; (4) likely net positive consequences from implementing the GPS and (5) clear link to the indirect evidence. We assessed guideline quality using the Appraisal of Guidelines for Research and Evaluation II tool. Results 253 guidelines from 44 professional societies issued 3726 actionable statements. We classified 2375 (64%) as GPS; of which 27 (1%) were labelled as GPS by guideline developers. 5 (19%) were labelled as GPS by their authors but did not meet GPS criteria. Of the 2375 GPS, 85% were clear and actionable; 59% provided a rationale necessitating the message for healthcare practice, 24% reported the net positive consequences from implementing the GPS. Systematic collection of evidence was deemed impractical for 13% of the GPS, and 39% explained the chain of indirect evidence supporting GPS development. 173/2375 (7.3%) statements explicitly satisfied all five criteria. The guidelines' overall quality was poor regardless of the appropriateness of GPS development and labelling. Conclusions Statements that qualify as GPS are common in COVID-19 guidelines but are characterised by unclear designation and development processes, and methodological weaknesses.
VytisknoutZobrazeno: 29. 7. 2024 01:28